Apimeds Pharmaceuticals US APUS
NYSE APUS
$2.87 -0.29 (-9.18%)
As of: Oct 23, 2026 · 1:35 PM EDT

Apimeds Pharmaceuticals US (APUS) Net Income (2024 - 2026)

Updated

Apimeds Pharmaceuticals US's Net Income came in at -$9.48 million for Q2 2026, compared with -$2.67 million a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Net Income (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Apimeds Pharmaceuticals US reported Net Income of -$21.17 million; for FY2025, it was -$12.09 million.

  • Going back by year, Net Income was -$1.39 million in FY2024 and -$777,694 in FY2023.
  • The Q2 2026 figure represents the lowest quarterly Net Income in data going back to Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,133.17 Bn 1,101.76 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 634.79 Bn 554.65 Bn 17.30 Bn 210.00 Mn
3 AbbVie 506.40 Bn 479.51 Bn 12.70 Bn 3.62 Bn
4 Merck 357.93 Bn 312.31 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 292.69 Bn 256.68 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 265.19 Bn 238.87 Bn 12.86 Bn 2.51 Bn
7 Amgen 238.22 Bn 193.61 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 195.23 Bn 169.43 Bn 6.22 Bn -10.50 Bn
9 Pfizer 171.11 Bn 117.76 Bn 10.94 Bn -248.00 Mn
10 Apimeds Pharmaceuticals US 4.92 Mn -14.72 Mn - -20.17 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.17 Mn
Dec 31, 2025 -1.16 Mn
Sep 30, 2025 -1.78 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -311,633.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00
API Access

Apimeds Pharmaceuticals US Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income&ticker=APUS&period=max&api_key=YOUR_API_KEY